Assessment of clinical epidemiology, treatment patterns, and survival outcomes in epithelial ovarian cancer: a retrospective analysis from a tertiary cancer centre in North India

Authors

  • Jyoti Sharma Department of Radiation Oncology, IGMC Shimla, Himachal Pradesh, India https://orcid.org/0000-0003-1517-3214
  • Manish Gupta Department of Radiation Oncology, IGMC Shimla, Himachal Pradesh, India
  • Vandana Thakur Department of Radiation Oncology, IGMC Shimla, Himachal Pradesh, India
  • Vikas Fotedar Department of Radiation Oncology, IGMC Shimla, Himachal Pradesh, India
  • Sidharth Vats Department of Radiation Oncology, IGMC Shimla, Himachal Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20241433

Keywords:

Cytoreduction, Survival outcomes in ovarian cancer, Advanced OC, Epithelial ovarian cancer, Cytoreduction surgery

Abstract

Background: Ovarian cancer stands as the daunting third most prevalent cancer among females. The aim of this study is to assess the clinical epidemiology, treatment patterns (including end-of-life care), and survival outcomes among patients diagnosed with epithelial ovarian cancer.

Methods: This retrospective analysis encompassed all patients diagnosed with epithelial ovarian cancer and enrolled at the tertiary cancer center, IGMC Shimla in Himachal Pradesh. The study included patients registered between January 2014 and December 2018, spanning all age groups.

Results: During the aforementioned period, ovarian cancer accounted for 18.7% of gynaecological cancers among females out of which epithelial ovarian cancer accounted for 14.8% of the cases. The median age of patients diagnosed with epithelial ovarian cancer (EOC) was 54.5 years. Most patients hailed from Shimla, followed by Mandi and Kullu districts, among the twelve districts in the state of Himachal Pradesh. The majority of patients were diagnosed at advanced stages FIGO III and IV, comprising a total of 77.1%. Chief complaints included abdominal pain, followed by abdominal distention, heaviness, or bloating. The median duration of follow-up was 27 months (with a standard deviation of ±9.175). The median overall survival (OS) for stage I, II, III, and IV was 92.59 months, 87 months, 82.17 months, and 52.5 months, respectively, and these differences were statistically significant.

Conclusions: Ovarian cancer patients are often diagnosed in advanced stages III and IV, primarily due to late diagnosis and the presence of vague symptoms. Achieving optimal cytoreduction significantly improves overall survival. Therefore, it's crucial to raise awareness among general physicians in rural healthcare settings and the public about the symptoms of ovarian cancer to facilitate early detection. Additionally, there's a notable deficiency in end-of-life discussions and palliative care management, which should be accessible to every patient.

References

Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Glob Oncol. 2020;6:1063-75.

Meena RK, Syed NA, Sheikh ZA, Guru FR, Mir MH, Banday SZ, et al. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022;8:e2200032.

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-45.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-8.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080-7.

Ravindran A, Sood R, Negi K. A prospective observational to study sociodemographic profile, clinical profile and pattern of gynaecological malignancies in a tertiary care center in Himachal Pradesh. Int J Reprod Contracept Obstet Gynecol. 2021;10:4263-6.

Puri S, Chadha V, Pandey A. Epidemiology of ovarian tumours in Northern India - A tertiary hospital based study. Indian J Comm Fam Med. 2018;4:37-41.

Mondal SK, Banyopadhyay R, Nag DR, Roychowdhury S, Mondal PK, Sinha SK. Histologic pattern, bilaterality and clinical evaluation of 957ovarian neoplasms: A 10-year study in a tertiary hospital of eastern India. J Can Res Ther. 2011;7:4337.

Maheshwari A, Kumar N, Gupta S, Rekhi B, Shylasree TS, Dusane R, et al. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Indian J Cancer. 2018;55(1):50-4.

Murthy NS, Shalini S, Suman G, Pruthvish S, Mathew A. Changing trends in incidence of ovarian cancer - the Indian scenario. Asian Pac J Cancer Prev. 2009;10(6):1025-30.

Li K, Husing A, Fortner R, Tj0nneland A, Hansen L, Dossus L, et al. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study. British J Cancer. 2015;112:1257-65.

Dhiman P, Bapsy PP, Patil CN, Raghupathi R. Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer? South Asian J Cancer. 2022;11(3):207-12.

Inci MG, Rasch J, Woopen H, Mueller K, Richter R, Sehouli J. ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN-trial). Arch Gynecol Obstet. 2021;304(5):1323-33.

Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023:PMID: 33620837.

Micci F, Haugom L, Ahlquist T, Abeler VM, Trope CG, Lothe RA, Heim S. Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution. J Oncol. 2010;2010:646340.

Kumari A, Singh N. Clinical profile of patients presenting with ovarian tumors at a tertiary care teaching hospital in Jharkhand, India. Int J Contemp Med Res. 2020;7(7):G5-91.

Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020;17(10):e1003295.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-59.

Marrelli D, Ansaloni L, Federici O, Asero S, Carbone L, Marano L, et al. Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes. Cancers (Basel). 2022;14(23):6010.

Nieuwenhuyzen-de Boer GM, Aamran H, van den Berg CB, Willemsen S, Piek JMJ, Reesink-Peters N, et al. Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients. Cancers (Basel). 2023;15(15):3947.

Downloads

Published

2024-05-29

Issue

Section

Original Research Articles